Biomed Life Science Day
November 2, 2023 | 5pm
Mövenpick Hotel Basel
Dear guests,
We are delighted to invite you to the Biomed Life Science Day on November 2, 2023 at 5pm at Mövenpick Hotel Basel. Please join us for an evening packed with insights into the world of Biotech entrepreneurship, venture capital and selected portfolio companies. Apéro riche and networking to follow.
Agenda
Perspectives from a large corporate on the role and impact of Venture Capital in the Life Sciences industry.
Insights on targeting high-value cancer targets with a novel drug type, by Dimericon Therapeutics, BiomedInvest IV's first portfolio company.
Successful entrepreneurs discuss what it takes to exit an early-stage biotech company.
Updates on BiomedInvest III portfolio and the launch of Biomed's fourth venture capital fund, BiomedInvest IV.
Speakers
Dr. Thomas Schweins is Head of the Life Science Business Area at Qiagen, where he previously served as the Vice President of Marketing & Strategy and Head of HR. Prior to Qiagen, he worked as a Technology Manager at the Boston Consulting Group and as an Assistant to the Management Board at Hoechst/Aventis. Dr. Schweins holds a PhD from the Max Planck Institute of Biochemistry.
Carsten Dehning is CFO at Emergence Therapeutics and a member of the Executive Board, having joined the company at the founding stage. He previously fulfilled CEO and CFO roles at a number of healthcare companies including DeveloGen, Aspireo Pharmaceuticals, Albireo, Biovertis and Bourn Hall International. Mr Dehning holds a Diploma in business administration from the University of Göttingen, Germany.
Dr. Nicole Faust is the Managing Director of CEVEC Pharmaceuticals, a leading German cell line development and viral vector manufacturer, recently acquired by Cytiva. Before joining CEVEC, she held leadership positions with Lonza and Taconic Biosciences. Dr. Faust holds a PhD in cell and molecular biology from University of Freiburg and an MBA from Educatis University, Switzerland.
Dr. Mireia Gomez-Angelats is the CBO at Topas Therapeutics, a German clinical-stage biotech developing treatments for autoimmune and inflammatory diseases. She has over 20 years pharmaceutical experience covering R&D and business development/licensing (BD&L), with roles at Novartis, Bristol Myers Squibb, Janssen and Almirall. Dr. Gomez-Angelats holds a PhD in biochemistry and molecular biology from the University of Barcelona, Spain.
Dr. Michael Wacker is a serial entrepreneur and Managing Partner at BioMedPartners and BiomedVC. He previously co-founded and served as CSO of GlycoVaxyn, a specialist vaccine biopharmaceutical company, acquired by GSK for $212M in 2015. He serves as a board member to several biotech companies and as an Innosuisse startup coach. Dr. Wacker holds a Dr. nat. sc. in Microbiology from ETH Zürich.
Dr. Ulrich Kessler is the co-founder and CEO of Dimericon Therapeutics, a Swiss-based biotech startup, and first portfolio company of BiomedInvest IV. He previously co-founded and served as CEO of Inthera Bioscience and Pike Pharma. Dr. Kessler holds a Dr. sc. nat. from ETH Zürich and previously held roles at Boston Consulting Group, Roche & Prionics.
Location
Mövenpick Hotel Basel
Aeschengraben 25
4051 Basel
The hotel is located across the road from the Basel SBB train station. Trains arrive and depart at regular intervals. To get to the hotel by car, go towards Basel City on the A3 motorway, take the exit 5 and follow the 12 until Aeschengraben. Parking spaces are available on-site. The event will be held in the Topaz meeting room.